Results 261 to 270 of about 53,113 (297)

Atezolizumab and Bevacizumab Induced Diabetes Mellitus and Myocarditis: A Case Report. [PDF]

Cureus
Mirza MA, Periyasami V, Kasi A, Pampapathi K, Sagi SV.   +4 more
europepmc   +1 more source

A Rare Case of Atezolizumab-Induced Very Severe Aplastic Anemia. [PDF]

Cureus
Vadlapatla V, Truong RD, Tseng JE.
europepmc   +1 more source

Evaluation of prognostic scores in patients with HCC undergoing first-line immunotherapy with atezolizumab and bevacizumab

Simon Johannes Gairing, Philipp Mildenberger, Jennifer Gile, Fabian Jost‐Brinkmann, Bernhard Scheiner, Catherine Leyh, Sabine Lieb, Friedrich Sinner, Vincent Jörg, Thorben Fruendt, Vera Himmelsbach, Nada Abedin, Cennet Şahin, Katrin Böttcher, Jasmin Schuhbaur, Simon Labuhn, James Korolewicz, Claudia Angela Maria Fulgenzi, Antonio D’Alessio, Valentina Zanuso, Florian Hucke, Natascha Röhlen, Najib Ben Khaled, Eleonora Ramadori, Lukáš Müller, Arndt Weinmann, Roman Kloeckner, Peter R. Galle, Nguyen H. Tran, Sudhakar K. Venkatesh, Andreas Teufel, Matthias P. Ebert, Enrico N. De Toni, Dirk‐Thomas Waldschmidt, Jens U. Marquardt, Dominik Bettinger, Markus Peck‐Radosavljevic, Andreas Geier, Florian P. Reiter, Lorenza Rimassa, David J. Pinato, Christoph Roderburg, Thomas J. Ettrich, Michael Bitzer, Veit Scheble, Ursula Ehmer, Marie‐Luise Berres, Fabian Finkelmeier, Maria A. González-Carmona, Johann von Felden, Kornelius Schulze, Marino Venerito, Florian van Bömmel, Leonie Jochheim, Matthias Pinter, Raphael Mohr, Sumera I. Ilyas, Irene Schmidtmann, Friedrich Foerster   +58 more
openalex   +1 more source

Non-small cell lung cancer molecular subtypes and vulnerability to immunotherapy treatment combinations. [PDF]

Nat Commun
Lu T, Hamidi H, Socinski MA, Reck M, Cappuzzo F, Barlesi F, Jotte RM, Müller S, Qamra A, Amitai A, Guan X, Fuentes E, Koeppen H, Giltnane JM, Shames DS, Ballinger M, He MX, Wang Y, Srivastava MK, Nabet BY.   +19 more
europepmc   +1 more source

Cost-effectiveness analysis of cabozantinib plus atezolizumab for advanced hepatocellular carcinoma. [PDF]

Front Pharmacol
Zhu Y, He C, Cao SC, Li HJ, Cai RX, Bai ZJ, Xia TX.   +6 more
europepmc   +1 more source

Biomarker prediction of immunotherapy response in breast cancer: from single markers to multi-omics integration. [PDF]

NPJ Breast Cancer
Sanjari Moghaddam A, Lu KY, Nasrollahi E, Oji L, Homeniuk A, Amosu O, Chelysheva D, Brufsky AM.   +7 more
europepmc   +1 more source

Clinical Significance of Intratumoral Contrast Pooling on Contrast-Enhanced CT After Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma. [PDF]

Curr Oncol
Minamiguchi K, Irizato M, Nakano R, Kunichika H, Tachiiri T, Taiji R, Tsuji Y, Yasuda S, Yoshiji H, Sho M, Tanaka T.   +10 more
europepmc   +1 more source

Severe Anti-CV2/CRMP5, Anti-Hu, and Anti-SOX1 Antibody-Positive Paraneoplastic Neurological Syndrome Associated With Tumor Recurrence During Atezolizumab Therapy. [PDF]

Cureus
Tohge R, Utsumi K, Miki K, Wang C, Oki M, Fujii C, Kondo T.   +6 more
europepmc   +1 more source

PD-L1 inhibitors combined with chemotherapy for extensive-stage small cell lung cancer: a French nationwide cohort study. [PDF]

Lancet Reg Health Eur
Jourdain H, Albin N, Monard A, Desplas D, Zureik M, Haddy N.   +5 more
europepmc   +1 more source

The Use of Spatially Fractionated Radiation Therapy Combined With Immune Checkpoint Inhibitors and Vascular Endothelial Growth Factor Inhibitor in the Treatment of Giant Metastatic Hepatocellular Carcinoma: A Case Report. [PDF]

Adv Radiat Oncol
Jin Y, Qian L, Gu Y, Gu B, Shen C, Sun X.   +5 more
europepmc   +1 more source